Oncolytics Biotech, Inc. ONCY

NAS: ONCY | ISIN: CA6823108759   31/05/2024
1,070 USD (-0,93%)
(-0,93%)   31/05/2024

24 mei 2024 · Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action · Persbericht

16 mei 2024 · Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders · Persbericht

15 mei 2024 · Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial · Persbericht

9 mei 2024 · Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights · Persbericht

9 mei 2024 · Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer · Persbericht

8 mei 2024 · Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference · Persbericht

30 april 2024 · Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights · Persbericht

25 april 2024 · Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting · Persbericht

11 april 2024 · Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA · Persbericht

2 april 2024 · Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference · Persbericht

7 maart 2024 · Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights · Persbericht

5 maart 2024 · Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN · Persbericht

4 maart 2024 · Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights · Persbericht

28 februari 2024 · Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference · Persbericht

14 februari 2024 · Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort · Persbericht

9 januari 2024 · Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors · Persbericht

4 januari 2024 · Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024 · Persbericht

7 december 2023 · Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS · Persbericht

9 november 2023 · Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy · Persbericht

9 november 2023 · Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep · Persbericht

Mijn selecties